keyword
MENU ▼
Read by QxMD icon Read
search

pneumococcal conjugate vaccine

keyword
https://www.readbyqxmd.com/read/28723870/osteoarticular-infections-caused-by-streptococcus-pneumoniae-in-children-in-the-post-pneumococcal-conjugate-vaccine-era
#1
Liset Olarte, Jose Romero, William Barson, John Bradley, Philana Ling Lin, Laurence Givner, Tina Tan, Jill Hoffman, Kristina G Hultén, Edward O Mason, Sheldon L Kaplan
BACKGROUND: Pneumococcal osteoarticular infections (OAI) are an uncommon manifestation of invasive pneumococcal disease (IPD). We describe the demographic characteristics, hospitalization rate, serotype distribution and antibiotic susceptibility of children with pneumococcal OAI over a 16-year period. METHODS: We identified patients ≤18 years old with pneumococcal OAI at 8 children's hospitals in the United States (2000-2015). Pneumococcal isolates were collected prospectively...
July 18, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28719500/a-randomized-controlled-study-of-a-fully-liquid-dtap-ipv-hb-prp-t-hexavalent-vaccine-for-primary-and-booster-vaccinations-of-healthy-infants-and-toddlers-in-latin-america
#2
Pío López, Adriano Arguedas Mohs, Arturo Abdelnour Vásquez, Maria Consuelo-Miranda, Emmanuel Feroldi, Fernando Noriega, Emilia Jordanov, Siham B'Chir, Betzana Zambrano
BACKGROUND: Hexavalent diphtheria (D)-tetanus (T)-acellular pertussis (aP)-inactivated poliovirus (IPV)-hepatitis B (HB)-Haemophilus influenzae type b (PRP-T)-containing vaccines are increasingly the standard of care. This study evaluated the primary series (NCT01177722) and booster (NCT01444781) of a fully liquid DTaP-IPV-HB-PRP-T vaccine in Latin America. METHODS: Infants (N=1375) received HB vaccine at birth and were randomized to one of three batches of the investigational DTaP-IPV-HB-PRP-T or licensed control vaccine (DTaP-HB-IPV//PRP-T) at 2-4-6 months of age, co-administered with 7-valent pneumococcal conjugate vaccine (PCV7) (2-4-6 months) and rotavirus vaccine (2-4 months)...
July 14, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28719496/safety-and-immunogenicity-of-13-valent-pneumococcal-conjugate-vaccine-in-children-aged-6-to-17-years-in-india-an-open-label-trial
#3
Sharad Agarkhedkar, Christine Juergens, Krishnamurthy Balasundaram, Shalaka Agarkhedkar, Vani Sundaraiyer, Natacha Le Dren-Narayanin, Mark W Cutler, William C Gruber, Daniel A Scott, Beate Schmoele-Thoma
In an open-label study in India, 200 healthy participants aged 6-17 years received 13-valent pneumococcal conjugate vaccine (PCV13). PCV13 elicited robust functional antibody immune responses. No adverse events were reported by caregivers at the 1-month follow-up visit. The immunogenicity results together with the known favorable risk-benefit profile of PCV13 support extension of the indication to this age group in India.ClinicalTrials.gov: NCT02034877.
July 15, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28716556/impact-of-pneumococcal-conjugate-vaccine-pcv7-and-pcv13-on-pneumococcal-invasive-diseases-in-italian-children-and-insight-into-evolution-of-pneumococcal-population-structure
#4
Romina Camilli, Fabio D'Ambrosio, Maria Del Grosso, Fernanda Pimentel de Araujo, Maria Grazia Caporali, Martina Del Manso, Giovanni Gherardi, Fortunato D'Ancona, Annalisa Pantosti
BACKGROUND: The use of PCV7 for children immunization was gradually implemented in the Italian regions starting from 2006 and was replaced by PCV13 in 2010-2011. In this study we aimed to assess the PCV impact on invasive pneumococcal diseases (IPD) incidence, serotype distribution and antibiotic resistance in Italian children under 5years old. METHODS: All IPD cases in children from 5 Italian regions (Emilia-Romagna, Lombardia, A. P. Bolzano, A. P. Trento, and Piemonte) reported through the nationwide surveillance system during 2008-2014 were included in this study...
July 14, 2017: Vaccine
https://www.readbyqxmd.com/read/28712384/the-epidemiology-of-invasive-pneumococcal-disease-in-older-adults-in-the-post-pcv-era-has-there-been-a-herd-effect
#5
M Corcoran, I Vickers, J Mereckiene, S Murchan, S Cotter, M Fitzgerald, M McElligott, M Cafferkey, D O'Flanagan, R Cunney, H Humphreys
The 7 and 13-valent pneumococcal conjugate vaccines (PCVs) have reduced the incidence of invasive pneumococcal disease (IPD) in children in many countries. The objective of this work was to assess the impact of PCVs and potential herd-protection in older adults in Ireland. IPD notification and typing data from adults ⩾65 years of age from July 2007 to June 2016 was assessed using national surveillance data. There was a 94% reduction in PCV7 serotypes from 2007-2008 to 2015-2016, incidence rate ratio (IRR 0·05, P < 0·0001)...
August 2017: Epidemiology and Infection
https://www.readbyqxmd.com/read/28711389/population-genetic-structure-antibiotic-resistance-capsule-switching-and-evolution-of-invasive-pneumococci-before-conjugate-vaccination-in-malawi
#6
Chrispin Chaguza, Jennifer E Cornick, Cheryl P Andam, Rebecca A Gladstone, Maaike Alaerts, Patrick Musicha, Chikondi Peno, Naor Bar-Zeev, Arox W Kamng'ona, Anmol M Kiran, Chisomo L Msefula, Lesley McGee, Robert F Breiman, Aras Kadioglu, Neil French, Robert S Heyderman, William P Hanage, Stephen D Bentley, Dean B Everett
INTRODUCTION: Pneumococcal infections cause a high death toll in Sub Saharan Africa (SSA) but the recently rolled out pneumococcal conjugate vaccines (PCV) will reduce the disease burden. To better understand the population impact of these vaccines, comprehensive analysis of large collections of pneumococcal isolates sampled prior to vaccination is required. Here we present a population genomic study of the invasive pneumococcal isolates sampled before the implementation of PCV13 in Malawi...
July 12, 2017: Vaccine
https://www.readbyqxmd.com/read/28711388/impact-of-13-valent-pneumococcal-conjugate-vaccine-on-pneumococcal-meningitis-in-children
#7
Jesus Ruiz-Contreras, Juan Picazo, Juan Casado-Flores, Fernando Baquero-Artigao, Teresa Hernández-Sampelayo, Enrique Otheo, Cristina Méndez, María Del Amo, César Balseiro
OBJECTIVES: To evaluate the impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children. METHODS: Children younger than 15years of age attending 27 hospitals in the Region of Madrid with confirmed pneumococcal meningitis were identified in a prospective surveillance study, from 2007 to 2015. Clinical data, neurological sequelae, pneumococcal vaccination status, serotyping and antibiotic susceptibility were recorded. RESULTS: One hundred and four cases of pneumococcal meningitis were identified, 63 during the period of routine 7-valent pneumococcal conjugate vaccine immunisation (May 2007-April 2010) and 41 during the period of 13-valent pneumococcal conjugate vaccine immunisation (May 2010-April 2015)...
July 12, 2017: Vaccine
https://www.readbyqxmd.com/read/28711387/serotype-distribution-and-antimicrobial-susceptibility-pattern-in-children%C3%A2-5years-with-invasive-pneumococcal-disease-in-india-a-systematic-review
#8
REVIEW
Jyotsana Singh, Suba Sundaresan, Anand Manoharan, Anita Shet
BACKGROUND: Streptococcus pneumoniae is a leading cause of childhood diseases that result in significant morbidity and mortality in India. Commercially licensed and available pneumococcal conjugate vaccines (PCVs) include ten (PCV-10) and 13 (PCV-13) pneumococcal serotypes. Vaccines with other serotype combinations are under development. Reviewing and reporting trends and distribution of pneumococcal serotypes causing invasive pneumococcal disease in India will be useful for policy making as PCV is being introduced into India's universal immunization program...
July 12, 2017: Vaccine
https://www.readbyqxmd.com/read/28704347/pneumococcal-vaccination-among-medicare-beneficiaries-occurring-after-the-advisory-committee-on-immunization-practices-recommendation-for-routine-use-of-13-valent-pneumococcal-conjugate-vaccine-and-23-valent-pneumococcal-polysaccharide-vaccine-for-adults-aged
#9
Carla L Black, Walter W Williams, Rob Warnock, Tamara Pilishvili, David Kim, Jeffrey A Kelman
On September 19, 2014, CDC published the Advisory Committee on Immunization Practices (ACIP) recommendation for the routine use of 13-valent pneumococcal conjugate vaccine (PCV13) among adults aged ≥65 years, to be used in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) (1). This replaced the previous recommendation that adults aged ≥65 years should be vaccinated with a single dose of PPSV23. As a proxy for estimating PCV13 and PPSV23 vaccination coverage among adults aged ≥65 years before and after implementation of these revised recommendations, CDC analyzed claims for vaccination submitted for reimbursement to the Centers for Medicare & Medicaid Services (CMS)...
July 14, 2017: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/28702308/pneumococcal-conjugate-vaccine-implementation-in-middle-income-countries
#10
REVIEW
Serena Tricarico, Hannah C McNeil, David W Cleary, Michael G Head, Victor Lim, Ivan Kok Seng Yap, Chong Chun Wie, Cheng Siang Tan, Mohd Nor Norazmi, Ismail Aziah, Eddy Seong Guan Cheah, Saul N Faust, Johanna M C Jefferies, Paul J Roderick, Michael Moore, Ho Ming Yuen, Marie-Louise Newell, Nuala McGrath, C Patrick Doncaster, Alex R Kraaijeveld, Jeremy S Webb, Stuart C Clarke
BACKGROUND: Since 2000, the widespread adoption of pneumococcal conjugate vaccines (PCVs) has had a major impact in the prevention of pneumonia. Limited access to international financial support means some middle-income countries (MICs) are trailing in the widespread use of PCVs. We review the status of PCV implementation, and discuss any needs and gaps related to low levels of PCV implementation in MICs, with analysis of possible solutions to strengthen the PCV implementation process in MICs...
2017: Pneumonia
https://www.readbyqxmd.com/read/28700264/overall-effectiveness-of-pneumococcal-conjugate-vaccines-an-economic-analysis-of-phid-cv-and-pcv-13-in-the-immunization-of-infants-in-italy
#11
Paolo Castiglia, Lorenzo Pradelli, Stefano Castagna, Veronica Freguglia, Giorgio Palù, Susanna Esposito
Pneumococcal diseases are associated with a significant clinical and economic burden. The 7-valent pneumococcal conjugate vaccine (PCV-7) has been used for the immunization of newborns against invasive pneumococcal diseases (IPD) in Italy while now the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) and the 13-valent pneumococcal conjugate vaccine (PCV-13) are available. The aim of this analysis was to compare the estimated health benefits, cost and cost-effectiveness of immunization strategies vs...
July 12, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28696824/age-appropriate-versus-up-to-date-coverage-of-routine-childhood-vaccinations-among-young-children-in-israel
#12
Chen Stein-Zamir, Avi Israeli
BACKGROUND AND AIMS: Routine childhood vaccinations schedules recommend that children receive the vaccine doses at specific ages. Vaccination coverage data are conventionally reported by the up-to-date method. We aimed to assess vaccination timeliness by the age-appropriate method and compare to the up-to-date vaccination coverage. METHODS: Assessment of age-appropriate and up-to-date vaccination coverage among children born in Israel in 2009 and followed to age 48 months (national representative sample, n = 3892)...
July 11, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28696530/immunogenicity-and-safety-of-single-dose-13-valent-pneumococcal-conjugate-vaccine-in-pediatric-and-adolescent-oncology-patients
#13
Te-Yu Hung, Rishi S Kotecha, Christopher C Blyth, Sarah K Steed, Ruth B Thornton, Anne L Ryan, Catherine H Cole, Peter C Richmond
BACKGROUND: Children receiving immunosuppressive treatment for cancer are at high risk for invasive pneumococcal disease. The 13-valent pneumococcal conjugate vaccine (PCV13) can prevent pneumococcal disease in healthy children; however, there is an absence of literature regarding the benefit of PCV13 in immunocompromised children with cancer. METHODS: A prospective, open-label cohort study recruited children between ages 1 and 18 years who were receiving active immunosuppressive therapy (AIT) or were within 12 months after completing immunosuppressive therapy (CIT)...
July 11, 2017: Cancer
https://www.readbyqxmd.com/read/28694854/antimicrobial-resistant-pattern-and-capsular-typing-of-streptococcus-pneumoniae-isolated-from-children-in-sistan-baluchestan
#14
Zahra Gharailoo, Seyed Fazlollah Mousavi, Niloofar Halvani, Mohammad Mehdi Feizabadi
BACKGROUND: Ankyloglossia is an anatomic developmental anomaly determining by thick and short, fi brotic ferenum. Tongue changes have severe eff ects on occlusion and oropharyngeal structures. The aim of this study was to evaluate the position of hyoid in children 7-11 years` old with ankyloglossia in lateral cephalometric radiographs. MATERIALS AND METHOD: In this study 260 nasopharyngeal swabs were taken from non-vaccinated healthy children between 6 months to 6 years old at medical centers in Sistan-Baluchestan during August 2013 to January 2014...
September 2016: Mædica
https://www.readbyqxmd.com/read/28694340/colonisation-of-irish-patients-with-chronic-obstructive-pulmonary-disease-by-streptococcus-pneumoniae-and-analysis-of-the-pneumococcal-vaccine-coverage-a-non-interventional-observational-prospective-cohort-study
#15
Hannah McCarthy, Mandy Jackson, Mary Corcoran, Martha McElligott, Elaine MacHale, Imran Sulaiman, Breda Cushen, Richard W Costello, Hilary Humpreys
OBJECTIVES: To characterise the pattern of colonisation and serotypes of Streptococcus pneumoniae among patients with chronic obstructive pulmonary disease (COPD) who currently receive the 23-valent pneumococcal polysaccharide vaccine (PPV-23) according to vaccination status, use of antibiotics and steroids. To investigate the prevalence of PPV-23 and 13-valent pneumococcal conjugate vaccine (PCV-13) serotypes within the study cohort. DESIGN: A non-interventional, observational, prospective cohort study with a 12 -month follow-up period inclusive of quarterly study visits...
July 9, 2017: BMJ Open
https://www.readbyqxmd.com/read/28693751/cost-effectiveness-of-13-valent-pneumococcal-conjugate-vaccine-pcv13-in-older-australians
#16
S Dirmesropian, J G Wood, C R MacIntyre, P Beutels, P McIntyre, R Menzies, J F Reyes, C Chen, A T Newall
BACKGROUND: The 23-valent pneumococcal polysaccharide vaccine (PPV23) has been funded under the Australia National Immunisation Program (NIP) since January 2005 for those aged >65years and other risk groups. In 2016, PCV13 was accepted by the Pharmaceutical Benefits Advisory Committee (PBAC) as a replacement for a single dose of PPV23 in older Australian adults. METHODS: A single-cohort deterministic multi-compartment (Markov) model was developed describing the transition of the population between different invasive and non-invasive pneumococcal disease related health states...
July 7, 2017: Vaccine
https://www.readbyqxmd.com/read/28690025/invasive-pneumococcal-disease-caused-by-ceftriaxone-resistant-streptococcus-pneumoniae-in-taiwan
#17
Hao-Yuan Lee, Tsu-Lan Wu, Lin-Hui Su, Hsin-Chieh Li, Rajendra Prasad Janapatla, Chyi-Liang Chen, Cheng-Hsun Chiu
BACKGROUND: Invasive pneumococcal disease (IPD) was associated with mortality, but the risk factors associated with mortality remains controversial. METHODS: A retrospective cohort study was designed. All patients with IPD from 2011 to 2013 admitted in a medical center were screened and collected for their clinical presentations and laboratory characteristics. RESULTS: Approximately half of the 134 IPD isolates derived from these patients belonged to three major serotypes (19A, 6A and 3), which are included in 13-valent pneumococcal conjugate vaccine (PCV13), but not in 7-valent pneumococcal conjugate vaccine (PCV7)...
June 26, 2017: Journal of Microbiology, Immunology, and Infection, Wei Mian Yu Gan Ran za Zhi
https://www.readbyqxmd.com/read/28688781/immunogenicity-of-13-valent-pneumococcal-conjugate-vaccine-among-children-with-underlying-medical-conditions
#18
Sabelle Jallow, Shabir A Madhi, Richard Madimabe, Nosisa Sipambo, Avy Violari, Udai Kala, Karen Petersen, Sanushka Naidoo, Charl Verwey, David P Moore, Marta C Nunes
BACKGROUND: Streptococcus pneumoniae is a leading cause of vaccine-preventable disease in children under 5years. Immunocompromised children and those with underlying diseases are at increased risk of severe complications from vaccine-preventable infections. We studied the humoral immune response to the 13-valent pneumococcal conjugate vaccine (PCV13) in children with HIV-infection, kidney or lung disease and compared this to the response in healthy control children. METHODS: Children aged 12-71months with underlying conditions including HIV-infection and those with kidney and lung diseases (at-risk children), and a healthy control group were vaccinated with PCV13...
July 5, 2017: Vaccine
https://www.readbyqxmd.com/read/28687405/colonization-with-19f-and-other-pneumococcal-conjugate-vaccine-serotypes-in-children-in-st-louis-missouri-usa
#19
Michelle McFarland, Taylor P Szasz, Julie Y Zhou, Kara Motley, Janardan S Sivapalan, Megan Isaacson-Schmid, Elizabeth M Todd, Patrick G Hogan, Stephanie A Fritz, Carey-Ann D Burnham, Steen Hoffmann, Sharon Celeste Morley
BACKGROUND: The epidemiology of nasopharyngeal (NP) pneumococcal carriage varies with geography and has changed in response to pneumococcal conjugate vaccine (PCV): a low prevalence (3% or less of colonizing isolates) of colonization by vaccine-type (VT) pneumococcal serotypes after PCV introduction has been reported. The primary goal of this study was to determine the VT serotype prevalence of NP pneumococcal colonization of children residing in the St. Louis, MO, USA metropolitan area following introduction of the 13-valent PCV in 2010...
July 4, 2017: Vaccine
https://www.readbyqxmd.com/read/28680083/comparison-of-traditional-culture-and-molecular-qpcr-for-detection-of-simultaneous-carriage-of-multiple-pneumococcal-serotypes-in-african-children
#20
Courtney P Olwagen, Peter V Adrian, Shabir A Madhi
S. pneumoniae is a common colonizer of the human nasopharynx in high income and low-middle income countries. Due to limitations of standard culture methods, the prevalence of concurrent colonization with multiple serotypes is unclear. We evaluated the use of multiplex quantitative PCR (qPCR) to detect multiple pneumococcal serotypes/group colonization in archived nasopharyngeal swabs of pneumococcal conjugate vaccine naive children who had previously been investigated by traditional culture methods. Overall the detection of pneumococcal colonization was higher by qPCR (82%) compared to standard culture (71%; p < 0...
July 5, 2017: Scientific Reports
keyword
keyword
112012
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"